



MC-217

Lab No. : SG2/26-08-2024/SR9565375

Patient Name : BUDDHA DEB SAHA

Age : 34 Y 3 M 17 D

Gender : M

Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 26/Aug/2024 08:51AM

Report Date : 26/Aug/2024 03:38PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
*BILIRUBIN (TOTAL) , GEL SERUM			
BILIRUBIN (TOTAL) (Method:DIAZONIUM ION)	0.7	0.2 - 1.2	mg/dL
SGOT/AST,GEL SERUM (Method:UV WITH P5P)	34	15 - 37	U/L
SODIUM,BLOOD (Method:ISE INDIRECT)	<u>135</u>	136 - 145	mEq/L
CHLORIDE,BLOOD (Method:ISE INDIRECT)	<u>108</u>	98 - 107	mEq/L
CREATININE, BLOOD (Method: ALKALINE PICRATE)	0.85	0.70 - 1.30	mg/dl
PHOSPHORUS-INORGANIC,BLOOD (Method:UV PHOSPHOMOLYBDATE)	3.5	2.5-4.5 mg/dl	mg/dl
*TOTAL PROTEIN [BLOOD] ALB:GLO R	ATIO , .		
TOTAL PROTEIN (Method:BIURET METHOD)	7.4	6.6 - 8.7	g/dL
ALBUMIN (Method:BCP)	4	3.4 -5.0 g/dl	g/dl
GLOBULIN (Method:Calculated)	<u>3.4</u>	1.8-3.2	g/dl
AG Ratio (Method:Calculated)	1.18	1.0 - 2.5	
*GLYCATED HAEMOGLOBIN (HBA1C),	EDTA WHOLE BLOOD		
GLYCATED HEMOGLOBIN (HBA1C)	4.9	***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***	%
HbA1c (IFCC) (Method:HPLC)	30		mmol/mol

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Analyzer used : Bio-Rad D 10 Method : HPLC Cation Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease





Lab No.

: SG2/26-08-2024/SR9565375

: BUDDHA DEB SAHA

: 34 Y 3 M 17 D Age

Gender : M

Patient Name

: Sevoke Road, Siliguri 734001

: Dr.MEDICAL OFFICER

Collection Date : 26/Aug/2024 08:51AM

Report Date : 26/Aug/2024 03:38PM



DEPARTMENT OF BIOCHEMISTRY

Lab Add.

Ref Dr.

Test Name Result Bio Ref. Interval Unit

- . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B12/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References:

- Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

PDF Attached

(Method:CLIA)

1 D1 7 Rudened			
LIPID PROFILE, GEL SERUM			
CHOLESTEROL-TOTAL (Method:CHOLESTEROL OXIDASE, ESTERASE,PEROXIDASE)	190	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/dL	mg/dl
TRIGLYCERIDES (Method:ENZYMATIC, END POINT)	132	NORMAL < 150 BORDERLINE HIGH mg/dl 150-199 HIGH 200-499 VERY HIGH > 500	
HDL CHOLESTEROL (Method:DIRECT MEASURE-PEG)	42	NO RISK : >60 mg/dL, MODERATE RISK : 40-60 mg/dL, HIGH RISK : <40 mg/dL	•
LDL CHOLESTEROL DIRECT (Method:DIRECT MEASURE)	126	OPTIMAL: <100 mg/dL, Near mg/dl optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL	
VLDL	22	< 40 mg/dl	mg/dL
(Method:Calculated)	. =	LOW BIOLOGO A A AVERAGE BIOLO	
CHOL HDL Ratio (Method:Calculated)	<u>4.5</u>	LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	
BILIRUBIN (DIRECT) (Method:DIAZOTIZATION)	0.2	< 0.2	mg/dL
ALKALINE PHOSPHATASE (Method:P-NPP,AMP BUFFER)	84	46 - 116	U/L
UREA,BLOOD (Method:UREASE-COLORIMETRIC)	30	12.8-42.8	mg/dl
*THYROID PANEL (T3, T4, TSH), GEL SERUM	1		
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	0.96	0.60 - 1.81 ng/ml	ng/ml
T4-TOTAL (THYROXINE) (Method:CLIA)	6.1	4.5 - 10.9	microgram/dl
TSH (THYROID STIMULATING HORMONE)	1.91	0.35-5.5	μIU/mL

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Lab No. : SG2/26-08-2024/SR9565375





Patient Name : BUDDHA DEB SAHA

Age : 34 Y 3 M 17 D

Gender : M

Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 26/Aug/2024 08:51AM

Report Date : 26/Aug/2024 03:38PM



Test Name Result Bio Ref. Interval Unit

Trimester specific TSH LEVELS during pregnancy:
FIRST TRIMESTER : 0.10 2.50 µ IU/mL
SECOND TRIMESTER : 0.20 3.00 µ IU/mL
THIRD TRIMESTER : 0.30 3.00 µ IU/mL

References:

1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.

2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.

3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

URIC ACID,BLOOD (Method:URICASE ,COLORICMETRIC)	7.2	3.5 - 7.2	mg/dl
POTASSIUM,BLOOD (Method:ISE INDIRECT)	4.11	3.5 - 5.1	mEq/L
GLUCOSE,PP (Method:Hexokinase Method)	93	75-140	mg/dl
SGPT/ALT (Method:UV WITH P5P)	42	16 - 63	U/L
CALCIUM,BLOOD (Method:OCPC)	9.1	8.6-10.0 mg/dl	mg/L
GLUCOSE,FASTING (Method:Hexokinase Method)	87	70 - 100	mg/dl

*** End Of Report ***

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

Lab No. : SG2/26-08-2024/SR9565375









Patient Name : BUDDHA DEB SAHA

Age : 34 Y 3 M 17 D

Gender : M

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 26/Aug/2024 08:57AM

Report Date : 27/Aug/2024 04:20PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
-----------	--------	-------------------	------	--

URIC ACID, URINE, SPOT URINE

URIC ACID, SPOT URINE

(Method:URICASE)

ESTIMATED TWICE

<u>20</u>

37-92 mg/dL

mg/dL

To correlate clinically.

*** End Of Report ***

Dr. Sudeshna Baral M.B.B.S MD. (Biochemistry) (Consultant Biochemist) Reg No. WBMC 64124

Lab No. : SG2/26-08-2024/SR9565375





Page 5 of 12

Lab No. : SG2/26-08-2024/SR9565375

Patient Name : BUDDHA DEB SAHA

: M

Age : 34 Y 3 M 17 D Gender

Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 26/Aug/2024 08:51AM

Report Date : 26/Aug/2024 06:01PM



DEPARTMENT OF HAEMATOLOGY

Τe	est Name	Result	Bio Ref. Interval	Unit

ESR (ERYTHROCYTE SEDIMENTATION RATE	, EDTA WHOLE BLOOD
-------------------------------------	--------------------

1stHour 04 0.00 - 20.00 mm/hr mm/hr

(Method:Westergren)

CDC WITH DI ATELET (THROMBOCVTE)	COUNT		
CBC WITH PLATELET (THROMBOCYTE)	·		
HEMOGLOBIN (Method:SLS haemoglobin method)	15	13 - 17	g/dL
WBC (Method:DC detection method)	5.3	4 - 10	*10^3/µL
RBC	5.17	4.5 - 5.5	*10^6/µL
(Method:DC detection method) PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy) DIFFERENTIAL COUNT	223	150 - 450*10^3	*10^3/µL
NEUTROPHILS (Method:Flowcytometry/Microscopy)	59	40 - 80 %	%
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	33	20 - 40 %	%
MONOCYTES (Method:Flowcytometry/Microscopy)	03	2 - 10 %	%
EOSINOPHILS (Method:Flowcytometry/Microscopy)	05	1 - 6 %	%
BASOPHILS (Method:Flowcytometry/Microscopy)	00	0-0.9%	%
CBC SUBGROUP			
HEMATOCRIT / PCV (Method:Calculated)	45.7	40 - 50 %	%
MCV (Method:Calculated)	88.5	83 - 101 fl	fl
MCH (Method:Calculated)	29	27 - 32 pg	pg
MCHC (Method:Calculated)	32.8	31.5-34.5 gm/dl	gm/dl
RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated)	<u>14.8</u>	11.6-14%	%
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	16.8	8.3 - 25 fL	fL
MPV-MEAN PLATELET VOLUME (Method:Calculated)	11.1	7.5 - 11.5 fl	
RBC	NORMOCYTIC NORMOCHROMIC.		
WBC.	NORMAL MORPHOLOGY.		
PLATELET	ADEQUATE ON SMEAR.		

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

ABO 0

(Method:Gel Card)

POSITIVE

(Method:Gel Card)

Gel technology Dia Med ID Micro typing system is the latest technology in transfusion Medicine. It gives more reproducible and standardized test results.

> Lab No. SG2/26-08-2024/SR9565375





Lab No. : SG2/26-08-2024/SR9565375 Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER **Patient Name** : BUDDHA DEB SAHA : 34 Y 3 M 17 D **Collection Date** : 26/Aug/2024 08:51AM Age Gender Report Date : 26/Aug/2024 06:01PM



DEPARTMENT OF HAEMATOLOGY

Test Name Result Bio Ref. Interval Unit

It more repaid, reliable, very sensitive and objective, and hence more consistent and comparable results are obtained. Single used cards are individualised for every patient and results can be photographed / scanned and stored for future use. Special instruments that are used only for this technology also reduce risk of any contamination.

Ref:- WHO technical manual on transfusion medicine-Second Edition 2003

(RESULTS ALSO VERIFIED BY: FORWARD AND REVERSE GROUPING (TUBE AND SLIDE METHOD)

TECHNOLOGY USED: GEL METHOD

: M

ADVANTAGES:

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

*** End Of Report ***

MBBS, MD (Path), IFCAP **Consultant Pathologist** Reg. No. 65992 (WBMC)

Lab No. SG2/26-08-2024/SR9565375



Patient Name : BUDDHA DEB SAHA Ref Dr. : Dr.MEDICAL OFFICER

Age : 34 Y 3 M 17 D Collection Date

Gender : M Report Date : 26/Aug/2024 10:36AM



DEPARTMENT OF X-RAY

Lab Add.

DEPARTMENT OF RADIOLOGY X-RAY REPORT OF CHEST (PA)

FINDINGS:

- Cardiac size appears within normal limits. Margin is well visualised and cardiac silhoutte is smoothly outlined. Shape is within normal limit.
- Lung parenchyma shows no focal lesion. No general alteration of radiographic density. Apices are clear. Bronchovascular lung markings are within normal.
- · Lateral costo-phrenic angles are clear.
- Domes of diaphragm are smoothly outlined. Position is within normal limits.

IMPRE	SSION:
Norma	ıl studv.

*** End Of Report ***

DR. Ziaul Mustafa MD, Radiodiagnosis

Lab No. : SG2/26-08-2024/SR9565375 Page 7 of 12





MC-2176

 Patient Name
 : BUDDHA DEB SAHA
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 34 Y 3 M 17 D
 Collection Date
 : 26/Aug/2024 08:55AM

 Gender
 : M
 Report Date
 : 26/Aug/2024 03:56PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

URINE ROUTINE ALL, ALL, URINE			
PHYSICAL EXAMINATION			
COLOUR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION			
pH	5.0	4.6 - 8.0	
(Method:Dipstick (triple indicator method))			
SPECIFIC GRAVITY	1.020	1.005 - 1.030	
(Method:Dipstick (ion concentration method))	ABSENT	NOT DETECTED	
PROTEIN (Method:Dipstick (protein error of pH	ADSENT	NOT DETECTED	
indicators)/Manual)			
GLUCOSE	ABSENT	NOT DETECTED	
(Method:Dipstick(glucose-oxidase-peroxidase			
method)/Manual)	4 D O E N I T	NOT DETECTED	
KETONES (ACETOACETIC ACID,	ABSENT	NOT DETECTED	
ACETONE) (Method:Dipstick (Legals test)/Manual)			
BLOOD	ABSENT	NOT DETECTED	
(Method:Dipstick (pseudoperoxidase reaction))	ADOLIVI	NOT BETEGTED	
BILIRUBIN	ABSENT	NEGATIVE	
(Method:Dipstick (azo-diazo reaction)/Manual)			
UROBILINOGEN	ABSENT	NEGATIVE	
(Method:Dipstick (diazonium ion reaction)/Manual)			
NITRITE	ABSENT	NEGATIVE	
(Method:Dipstick (Griess test))	ADOENT	NICOATIVE	
LEUCOCYTE ESTERASE (Method:Dipstick (ester hydrolysis reaction))	ABSENT	NEGATIVE	
MICROSCOPIC EXAMINATION			
LEUKOCYTES (PUS CELLS)	0-1	0-5	/hnf
(Method:Microscopy)	0-1	0-5	/hpf
EPITHELIAL CELLS	0-1	0-5	/hpf
(Method:Microscopy)	÷ :		· · · · Iz ·
RED BLOOD CELLS	ABSENT	0-2	/hpf
(Method:Microscopy)			•
CAST	ABSENT	NOT DETECTED	
(Method:Microscopy)	4 D O E N I T	NOT DETECTED	
CRYSTALS	ABSENT	NOT DETECTED	
(Method:Microscopy)	FEW	NOT DETECTED	
BACTERIA (Method:Microscopy)	1 = VV	NOT DETECTED	
YEAST	ABSENT	NOT DETECTED	
(Method:Microscopy)			
OTHERS	ABSENT		

Note:

Lab No.

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can

Lab No. : SG2/26-08-2024/SR9565375 Page 8 of 12





Lab No. : SG2/26-08-2024/SR9565375 Lab Add. : Sevoke Road, Siliguri 734001

Patient Name : BUDDHA DEB SAHA Ref Dr. : Dr.MEDICAL OFFICER Age : 34 Y 3 M 17 D **Collection Date** : 26/Aug/2024 08:55AM Gender : M

Report Date : 26/Aug/2024 03:56PM



DEPARTMENT OF CLINICAL PATHOLOGY

Bio Ref. Interval **Test Name** Result Unit

occur due to cell lysis.

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

*** End Of Report ***

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

Page 9 of 12 Lab No. SG2/26-08-2024/SR9565375

E-mail: info@surakshanet.com | Website: www.surakshanet.com



Patient Name : BUDDHA DEB SAHA Ref Dr. : Dr.MEDICAL OFFICER

Age : 34 Y 3 M 17 D Collection Date

Gender : M Report Date : 26/Aug/2024 12:20PM



DEPARTMENT OF CARDIOLOGY

DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

Lab Add.

HEART RATE : 72 /min.

RHYTHM : Regular sinus.

P-WAVE : Normal

P-RINTERVAL : 160 ms,

QRS DURATION : 80 ms

QRS CONFIGURATION : NORMAL

QRS VOLTAGE : R/S in V1 2/2 mm.

R/S in V6 6/3 mm.

QRS AXIS : +30°

Q- Waves : No significant Q-wave.

QT TIME : Normal.

ST SEGMENT : Normal.

T WAVE : NORMAL

ROTATION : Normal.

OTHER FINDINGS : Nil.

IMPRESSION : ECG WITHIN NORMAL LIMIT.

*** End Of Report ***

Dr. ARABINDA SAHA (MD,DM)
CONSULTANT CARDIOLOGIST

Lab No. : SG2/26-08-2024/SR9565375 Page 10 of 12



Lab No. : SG2/26-08-2024/SR9565375 **Lab Add.**

Patient Name : BUDDHA DEB SAHA Ref Dr. : Dr.MEDICAL OFFICER

Age : 34 Y 3 M 17 D Collection Date :

Gender : M Report Date : 26/Aug/2024 05:22PM



DEPARTMENT OF ULTRASONOGRAPHY

DEPARTMENT OF ULTRASONOGRAPHY REPORT ON EXAMINATION OF WHOLE ABDOMEN

LIVER

Liver is normal in size (140 mm at right MCL) shows diffusely increased parenchymal echogenicity with maintained periportal & diaphragmatic echogenicity. No focal parenchymal lesion is evident. Intrahepatic biliary radicles are not dilated. Branches of portal vein are normal.

PORTA

The appearance of porta is normal. Common Bile duct is normal with no intraluminal pathology (Calculi /mass) could be detected at its visualised part. Portal vein is normal at porta.

GALL BLADDER

Gallbladder is physiologically distended. Wall thickness appears normal. No intraluminal pathology (Calculi/mass) could be detected. Sonographic Murphys sign is negative.

PANCREAS

Echogenecity appears within limits, without any focal lesion. Shape, size & position appears normal. No Calcular disease noted. Pancreatic duct is not dilated. No peri-pancreatic collection of fluid noted.

SPLEEN

Spleen is normal in size (81 mm). Homogenous and smooth echotexture without any focal lesion. Splenic vein at hilum appears normal. No definite collaterals could be detected.

KIDNEYS

Both kidneys are normal in shape, size (Rt. kidney 106 mm. & Lt. kidney 106 mm) axes & position. Cortical echogenecity appears normal maintaining corticomedullary differentiation. Margin is regular and cortical thickness is uniform. No calcular disease noted. No hydronephrotic changes detected.

URETERS

Visualised part of upper ureters are not dilated.

URINARY BLADDER

Urinary bladder is distended, wall thickness appeared normal. No intraluminal pathology (calculi / mass) could be detected.

PROSTATE

Prostate is normal in size. Echotexture appears within normal limits. No focal alteration of its echogenecity could be detectable.

It measures : 36 mm. x 29 mm. x 26 mm. Approximate weight could be around = 15 gms

IMPRESSION

Mild grade fatty infiltration in liver

Kindly note

<u>▶ Ultrasound is not the modality of choice to rule out subtle bowel lesion.</u>

▶ Please Intimate us for any typing mistakes and send the report for correction within 7 days.

Lab No. : SG2/26-08-2024/SR9565375



Patient Name

: BUDDHA DEB SAHA Ref Dr. : Dr.MEDICAL OFFICER

Age : 34 Y 3 M 17 D Collection Date :

Gender : M Report Date : 26/Aug/2024 05:22PM



DEPARTMENT OF ULTRASONOGRAPHY

The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

Lab Add.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

DR. Ziaul Mustafa

MD, Radiodiagnosis


Lab No. : SG2/26-08-2024/SR9565375 Page 12 of 12

Patient report

Sample ID: D02135827706

Injection date 26/08/2024 08:07 AM Injection #: 4 D-10 Method: HbA1c Rack #: --- Rack position: 4

Bio-Rad v: 5.00-2 S/N: #DM23F10804



Peak table - ID: D02135827706

Peak	R.time	Height	Area	Area %
Unknown	0.14	2502	5490	0.3
Unknown	0.18	2546	4106	0.2
A1a	0.23	3630	11729	0.5
A1b	0.30	6820	24527	1.2
F	0.53	1261	5988	0.3
LA1c/CHb-1	0.68	4275	34880	1.6
A1c	0.89	8872	72580	4.9
P3	1.36	28508	117913	5.5
A0	1.44	787220	1855499	87.0

Total Area: 2132713

Concentration:	%	mmol/mol
A1c	4.9	30